KalVista Pharmaceuticals Inc. Common Stock (KALV)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor in the Buffett and Graham tradition, I start with durable earnings, a strong balance sheet, and a margin of safety. KalVista does not offer much of that on the figures provided. It is a biopharmaceutical company developing oral therapies for rare diseases, including sebetralstat for hereditary angioedema and an oral Factor XIIa inhibitor program. It was taken private as of June 11, 2026, and the common stock closed at $27.00 on 2026-06-12 with a market capitalization of $965.0M. FairStock's calculations show a P/E of -6.85, based on the provided EPS figure of -$3.94 and that close, so there are no positive earnings to value. Trailing free cash flow is -$143.3M, and the FCF yield is -14.8%, meaning the company is consuming cash. Revenue growth, P/B, ROE, ROCE, and D/E are all unavailable in the data, which makes a Graham-style balance-sheet and return-on-capital assessment impossible. The provided profit growth of 55.03% sounds positive, but without a named filed period or positive earnings, I cannot treat it as durable earning power. The FairStock Score is 16/100, and the Lynch category is none because there are only 0 years of filed results and three are needed. The 52-week range is $10.41 to $27.00, so the price sits at the top of that range. A rare-disease oral therapy can have pricing power and a narrow moat if approved and adopted, but the figures given do not demonstrate it. The take-private event may now drive the shares more than fundamentals. I would need filed revenue, cash position, and clinical/commercial evidence before calling this a value opportunity.

In plain English: KalVista is a biopharmaceutical company that develops oral medicines for rare diseases, including a treatment for hereditary angioedema. It was taken private on June 11, 2026, and its numbers show losses and negative cash flow, so the business looks financially weak. At the June 12, 2026 close of $27.00, the price looks expensive relative to the reported losses and cash burn, though the take-private status may mean the stock trades on deal expectations rather than ordinary business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-06-12 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer